Unigestion Holding SA Sells 22,169 Shares of Cencora, Inc. (NYSE:COR)

Unigestion Holding SA cut its stake in shares of Cencora, Inc. (NYSE:COR - Free Report) by 14.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 127,820 shares of the company's stock after selling 22,169 shares during the quarter. Cencora accounts for 1.7% of Unigestion Holding SA's portfolio, making the stock its 19th largest holding. Unigestion Holding SA owned 0.07% of Cencora worth $28,719,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also modified their holdings of the company. Norges Bank acquired a new position in shares of Cencora in the 4th quarter valued at $478,309,000. Raymond James Financial Inc. acquired a new position in shares of Cencora in the fourth quarter worth about $322,460,000. Wellington Management Group LLP increased its position in shares of Cencora by 7.0% in the third quarter. Wellington Management Group LLP now owns 5,193,386 shares of the company's stock worth $1,168,927,000 after acquiring an additional 338,452 shares in the last quarter. Amundi raised its holdings in shares of Cencora by 30.8% during the fourth quarter. Amundi now owns 1,338,710 shares of the company's stock valued at $318,385,000 after acquiring an additional 314,846 shares during the period. Finally, Nordea Investment Management AB lifted its position in shares of Cencora by 40.2% in the 4th quarter. Nordea Investment Management AB now owns 1,077,272 shares of the company's stock valued at $243,173,000 after acquiring an additional 308,773 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Cencora

In other Cencora news, EVP Elizabeth S. Campbell sold 4,127 shares of the firm's stock in a transaction on Monday, March 24th. The shares were sold at an average price of $268.28, for a total value of $1,107,191.56. Following the sale, the executive vice president now directly owns 14,665 shares in the company, valued at $3,934,326.20. This trade represents a 21.96 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Chairman Steven H. Collis sold 14,578 shares of the business's stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $269.51, for a total transaction of $3,928,916.78. Following the transaction, the chairman now owns 317,913 shares in the company, valued at approximately $85,680,732.63. The trade was a 4.38 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 30,675 shares of company stock worth $8,034,778 over the last ninety days. Company insiders own 10.80% of the company's stock.

Analyst Ratings Changes

COR has been the topic of several research analyst reports. Bank of America lifted their price objective on shares of Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a research report on Friday. Wells Fargo & Company upped their price target on Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a research report on Friday, March 14th. StockNews.com upgraded Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. Evercore ISI upped their target price on Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a report on Thursday, February 6th. Finally, JPMorgan Chase & Co. raised their price target on shares of Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $284.20.

Cencora Stock Up 2.4 %

NYSE:COR traded up $6.69 during mid-day trading on Friday, reaching $285.84. The stock had a trading volume of 699,452 shares, compared to its average volume of 1,500,738. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. The stock has a market cap of $55.43 billion, a P/E ratio of 40.42, a PEG ratio of 1.31 and a beta of 0.55. The business's 50 day moving average is $259.61 and its 200 day moving average is $244.58. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $296.65.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. As a group, sell-side analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 0.77%. The ex-dividend date of this dividend was Friday, February 14th. Cencora's dividend payout ratio is 31.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.